Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie - LARVOL DELTA

Reserve antibiotics in paediatrics: single-centre clinical experience and antimicrobial stewardship implementation. (PubMed, Eur J Pediatr) - " Reserve antibiotic use in complex paediatric populations highlights the importance of characterizing our clinical experience of prescribing in real-world practice. In this context, the development and implementation of a structured institutional antimicrobial stewardship program represents a pragmatic strategy to improve clinical governance and guide the appropriate positioning of these last-resort agents."

Journal • Observational data • Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Oncology • Pediatrics

Comparative clinical outcomes of pandrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections in children. (PubMed, BMC Infect Dis) - "PDR A. baumannii and K. pneumoniae infections showed comparable severity and mortality in children, although K. pneumoniae affected younger patients and A. baumannii was associated with longer fever duration. Both pathogens were typically identified after prolonged hospitalization and were closely linked to intensive care exposure. The high rate of CZA resistance among PDR K. pneumoniae isolates, including all recurrent PDR K. pneumoniae episodes, was a clinically important finding that may further limit therapeutic options."

Clinical • Clinical data • Journal • Retrospective data • Critical care • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases

Distribution of ceftazidime-avibactam and colistin MIC values in carbapenem-resistant Klebsiella pneumoniae and its association with carbapenemase genotypes in Can Tho, Vietnam. (PubMed, Acta Microbiol Immunol Hung) - "The CAZ-AVI MIC differed significantly among genotypes (p = 0.002): isolates carrying blaKPC or blaOXA-48-like retained the highest susceptibility, whereas all isolates carrying only a metallo-β-lactamase (blaNDM or blaVIM) were resistant; the colistin MIC did not differ among genotypes (p = 0.376). Carbapenemase genotyping should guide the use of CAZ-AVI in this setting, particularly for distinguishing serine carbapenemase producers from MBL producers, while the elevated colistin MIC90 supports continued surveillance of colistin susceptibility."

Journal • Infectious Disease • Pneumonia

Systemic plus Local Antimicrobial Therapy for Post-Neurosurgical CRKP CNS Infections: A Case Series and Literature Review. (PubMed, World Neurosurg) - "Successful management rests on four principles: (1) definitive source control including device removal; (2) susceptibility-guided systemic/local therapy optimized by TDM; (3) immunocompromise is not a contraindication; and (4) delayed VPS placement (≥4 weeks off antibiotics). While infection control is achievable in 97%, good functional recovery remains limited."

Journal • CNS Disorders • Infectious Disease • Pneumonia • Ventriculomegaly

Breaking the deadlock of metallo-β-lactamases: evidence and prospects for Aztreonam/Avibactam. (PubMed, Emerg Microbes Infect) - "It is important to note that the combination of ceftazidime/avibactam (CZA) with ATM differs significantly from AZA in pharmacokinetic properties. The primary mechanisms of resistance involve mutations in the PBP3 gene, mutations and overexpression of β-lactamases, reduced outer membrane permeability, and overexpression of efflux pumps. Available data suggest that AZA is an important treatment option for severe infections caused by multidrug-resistant Enterobacterales, including MBL-producing strains, although pharmacoeconomic conclusions remain context-dependent."

Journal • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Phenotypic screening for metallo-β-lactamases and extended-spectrum β-lactamases in Pseudomonas aeruginosa using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards. (PubMed, Microbiol Spectr) - "However, these groups exhibit distinct susceptibility patterns to novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations, including ceftolozane/tazobactam (C/T), ceftazidime/avibactam (C/A), imipenem/relebactam (I/R), and meropenem/vaborbactam (M/V)...Antimicrobial susceptibility testing was performed using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards on 135 whole-genome-sequenced international CRPA isolates resistant by disc diffusion to ceftazidime, cefepime, imipenem, and/or meropenem...Our study identifies reliable screening cut-offs for MBL- and ESBL-production in CRPA using standard VITEK 2 and Phoenix automated AST panels. This readily available approach may accelerate detection, support routine laboratory workflows, reduce unnecessary confirmatory testing, and facilitate earlier targeted therapy and infection-control interventions in laboratories using these systems worldwide without requiring additional specialized testing or infrastructure."

Journal • Infectious Disease

Deciphering the genotypic profiles of Carbapenem-resistant Enterobacterales: A study from a tertiary care hospital in Bihar, India. (PubMed, New Microbes New Infect) - "Recommended therapies include Cefiderocol or Ceftazidime-avibactam plus Aztreonam. Continued molecular research and diagnostic enhancements remain critical."

Journal • Infectious Disease • Pneumonia

Multidrug-Resistant Organisms in Combat-Related Injuries: Insights from Iraq, Afghanistan, Ukraine, and Implications for Large-Scale Combat Operations. (PubMed, Mil Med) - "The MDRO burden in combat casualties is escalating in scale and severity, with direct implications for LSCO and PFC. Mitigation requires standardized antimicrobial protocols across Role 1 and Role 2 levels of care, centralized oversight by the Defense Health Agency, deployable rapid diagnostics, robust stewardship and infection-prevention programs, and resilient logistics-including drone-enabled medical resupply-to maintain antimicrobial effectiveness and operational readiness."

Journal • Infectious Disease • Pneumonia

Prevalence of Gram-negative ESKAPE pathogens in BAL fluid associated with severe lower respiratory tract infections: a 2025 retrospective study in Astana, Kazakhstan (ERS 2026) - "MDR/XDR phenotypes were detected: Ab-82.9%(XDR); Kp-67.6% (MDR), including meropenem (51%); Pa-47.2% (MDR), with ceftazidime/avibactam (33%). The BAL microbiota in SLRTI is dominated by extensively resistant Gram-negative ESKAPE isolates. Colistin maintained peak efficacy against Ab (100%) and Pa (98.1%). These findings underscore the imperative for pathogen-directed empirical strategies to optimize antimicrobial stewardship in high-risk cohorts."

Gram negative • Retrospective data • Infectious Disease • Pneumonia • Respiratory Diseases

Evaluation of the use of ceftazidime-avibactam and bedaquiline in the treatment of M. abscessus-pulmonary disease (ERS 2026) - "Our small cohort suggests that CA+Car+BDQ may be more efficacious and better tolerated than current first line regimens for MA-PD. Further studies are needed to allow for greater understanding of the safety and efficacy of this regimen."

Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Meropenem-Colistin Combination Mitigates Porin-Associated Carbapenem Resistance Development in Ertapenem-Mono-Resistant Enterobacterales. (PubMed, J Infect Dis) - "In ETP-mono-R Enterobacterales, subinhibitory carbapenem exposure promotes carbapenem resistance, with porin-associated mechanisms predominating in E. coli and K. pneumoniae. Co-exposure to COL attenuates this process, suggesting a potential strategy to delay the emergence of carbapenem resistance."

Journal • Infectious Disease • Pneumonia

Ceftazidime-avibactam in elastomeric pump for vascular graft infection: a case report. (PubMed, Infez Med) - "A subsequent isolate of K. pneumoniae demonstrated resistance to both ertapenem and ceftolozane-tazobactam.Treatment was transitioned to daptomycin (500 mg daily) and ceftazidime-avibactam (2.5 g three times a day), with oral rifampin added for anti-biofilm activity.To facilitate early discharge per the patient's request, ceftazidime-avibactam was administered off-label via an elastomeric pump. This case demonstrates that continuous 12-hour infusion of ceftazidime-avibactam via elastomeric pumps is a feasible and safe strategy for managing complex CRE infections in the OPAT setting. Such tailored approaches can enhance patient quality of life and reduce hospital stays, though further prospective studies are needed."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Infectious Disease • Metabolic Disorders • Peripheral Arterial Disease • Pneumonia

Evaluation of empiric intraoperative antibiotic regimens for coverage of donor-derived infection in lung transplantation: A single-center retrospective study (TTS 2026) - "The current empiric triple regimen of "vancomycin + imipenem + caspofungin" (used in 91.5% of cases) demonstrated an overall theoretical coverage rate of only 28.6% against DDI pathogens, with coverage rates of 20.0% against A. baumannii and 16.3% against carbapenem-resistant organisms...Commonly used adjusted antibiotics included polymyxin E (55.0%), eravacycline (45.0%), and ceftazidime-avibactam (37.5%).The composition of DDI pathogensthe theoretical coverage of existing antibiotic regimens against DDI pathogens The incidence of strictly defined DDI after lung transplantation at our center is 21.6%. The incidence of strictly defined DDI after lung transplantation at our center is 21.6%. Current empiric intraoperative antibiotic regimens provide limited coverage, particularly against multidrug-resistant organisms. An individualized, targeted intraoperative antibiotic prophylaxis strategy based on donor pathogen screening is urgently warranted."

Retrospective data • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Transplantation

Escherichia coli with penicillin-binding protein 3 insertions: implications for newer β-lactam/β-lactamase inhibitor combinations. (PubMed, Antimicrob Agents Chemother) - "Newer β-lactam/β-lactamase inhibitor combinations (ceftazidime/avibactam, aztreonam/avibactam, and cefepime/taniborbactam) and cefiderocol with affinities for PBP3 show reduced activity against E. coli with YRIN and YRIK insertions...In contrast, agents targeting PBP2, such as cefepime/zidebactam and cefiderocol-xeruborbactam, retain potent in vitro activity and will likely be important for future treatment strategies...There is an urgent need for enhanced global surveillance, along with rapid diagnostic tools capable of identifying PBP3 insertions and associated high-risk clones among carbapenemase-producing E. coli. Future strategies should prioritize agents with activities against multiple essential PBPs to preserve β-lactam efficacy."

Journal • Review

In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution. (PubMed, Antimicrob Agents Chemother) - "Cefiderocol failed to achieve stasis against a cefiderocol-resistant isolate. E219K impaired cefiderocol efficacy in vivo, supporting close monitoring of cefiderocol activity against isolates carrying this variant."

Journal • Preclinical • Infectious Disease

Ceftazidime-Avibactam With or Without Aztreonam Versus Other Active Antimicrobials in the Treatment of Bloodstream Infections by Carbapenem-Resistant Klebsiella pneumoniae. (PubMed, Infect Dis Ther) - "In this cohort, ceftazidime-avibactam with or without aztreonam was independently associated with lower 30-day mortality than OAAs in the treatment of CRKP BSIs. These findings extend the available evidence to BSIs caused by carbapenemase-producing isolates and support the need for broader access to ceftazidime-avibactam-based regimens in low- and middle-income countries, where therapeutic options remain limited."

Journal • Acute Kidney Injury • Infectious Disease • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases

Differential Antimicrobial Activity of Ceftazidime/Avibactam-Drug Combination Therapies Against Highly Drug-Resistant Acinetobacter baumannii (IDWeek 2026) - No abstract available

Combination therapy • Infectious Disease

Differential Effects of Ceftazidime/Avibactam plus Aztreonam, Cefiderocol, and Levofloxacin in Mono- versus Co-Culture of Pseudomonas aeruginosa and Stenotrophomonas maltophilia (IDWeek 2026) - No abstract available

Infectious Disease

Ceftolozane/Tazobactam (C/T) and Ceftazidime/Avibactam (CZA) Non-susceptibility (NS) Among Hospitalized Adults with Pseudomonas aeruginosa (PSA) Isolated from Lower Respiratory Tract (LTR) Clinical Cultures: Index and Subsequent Episodes in the Kaiser Permanente Southern California (KPSC) System (IDWeek 2026) - No abstract available

Infectious Disease

In vitro susceptibility of aztreonam combined with imipenem-relebactam and ceftazidime-avibactam in metallo-beta-lactamase producing Enterobacteriaceae (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease

Antimicrobial Susceptibility of KPC-Producing Enterobacterales and Molecular Characterization of Ceftazidime-Avibactam-Resistant Strains from United States Medical Centers (2018-2025). (IDWeek 2026) - No abstract available

Infectious Disease

Activity of Ceftazidime-Avibactam against Pseudomonas aeruginosa from Patients with Ventilator-Associated Pneumonia (VAP) from United States Medical Centers (2021-2025). (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

A Unique Cohort of Co-Infection-Free Difficult to Treat Pseudomonas aeruginosa Pneumonia: Mortality comparison of Aminoglycoside/ Fluoroquinolone/ Colistin Combination Based Regimen versus Ceftazidime/Avibactam or Ceftolozane/ Tazobactam. (IDWeek 2026) - No abstract available

Infectious Disease

Impact of Carbapenemase Class on 30-Day Mortality in Enterobacterales Bacteremia Treated with Ceftazidime-Avibactam with or without Aztreonam (IDWeek 2026) - No abstract available

Infectious Disease

Integrating CRRT as a Virtual Organ Into Physiologically Based Pharmacokinetic Modeling to Optimize Antimicrobial Dosing in Septic Patients. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "Vancomycin, meropenem, and ceftazidime-avibactam were selected as representative antimicrobial agents for model development and validated by graphical comparison with reported data, fold error, and geometric mean fold error (GMFE). The results showed that both GFR and CRRT intensity influenced drug exposure, with GFR showing a greater contribution. Overall, this study provides a quantitative method for predicting antimicrobial exposure and supports model-informed precision dosing in septic patients undergoing CRRT."

Journal • PK/PD data • Infectious Disease • Septic Shock